|1.||Raassina, Roope: 1 article (12/2005)|
|2.||Deramciclane Dose-Finding Study Group: 1 article (12/2005)|
|3.||Mäki-Ikola, Outi: 1 article (12/2005)|
|4.||Jokinen, Riitta: 1 article (12/2005)|
|5.||Kanerva, Harri: 1 article (12/2005)|
|6.||Rouru, Juha: 1 article (12/2005)|
|7.||Lepola, Ulla: 1 article (12/2005)|
|8.||Koponen, Hannu: 1 article (12/2005)|
|9.||Pohjalainen, Tiina: 1 article (12/2005)|
|10.||Penttinen, Jukka: 1 article (12/2005)|
03/01/1999 - "In conclusion, the 5-HT2 receptor antagonist anxiolytic drugs seem to be superior compared to the benzodiazepine type anxiolytic drug, chlordiazepoxide, as ritanserin and deramciclane improved sleep quality by increasing sleep episode length and time spent in DS, while chlordiazepoxide enhanced sleep fragmentation and decreased DS."
|2.||Anxiety Disorders (Anxiety Disorder)
12/01/2005 - "The aim of this double-blind, placebo-controlled, parallel-group study was to evaluate the efficacy, safety, and tolerability of a range of doses of deramciclane in patients with generalized anxiety disorder (GAD). "
12/01/2005 - "Deramciclane in the treatment of generalized anxiety disorder: a placebo-controlled, double-blind, dose-finding study."
02/01/2002 - "Egis, in collaboration with Orion Pharma and Pharmacia, is developing deramciclane, a 5-HT(2A) antagonist and a 5-HT(2C) inverse agonist, as a potential treatment for anxiety disorders . "